Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tempest Therapeutics, Inc. - Common Stock
(NQ:
TPST
)
0.8604
-0.0466 (-5.14%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
759,449
Open
0.9000
Bid (Size)
0.8800 (2)
Ask (Size)
0.9099 (7)
Prev. Close
0.9070
Today's Range
0.8601 - 0.9148
52wk Range
0.6986 - 6.000
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
February 10, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Performance
YTD
+0.23%
+0.23%
1 Month
-6.85%
-6.85%
3 Month
-5.98%
-5.98%
6 Month
-39.41%
-39.41%
1 Year
-77.94%
-77.94%
More News
Read More
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
January 06, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
November 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 30, 2024
Via
Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
October 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 10, 2024
Via
Benzinga
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
October 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 10, 2024
Via
Benzinga
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
October 10, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Extends Limited Duration Stockholder Rights Plan
October 10, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 20, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
September 18, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 23, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
August 21, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
August 15, 2024
Via
Benzinga
Exposures
Product Safety
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
August 15, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024
August 09, 2024
Via
InvestorPlace
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
$55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
July 05, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.